SignalFDA/Bio

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients.

What changed

CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients.

Why it matters

CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients. — impact context not separately stored; see What changed.

Sources

eodhd